VYGR
Voyager Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$229.60M
P/E Ratio
—
EPS
$-1.98
Beta
1.26
52W High
$5.55
52W Low
$2.65
50-Day MA
$3.93
200-Day MA
$4.07
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.44
PEG Ratio
0.00
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $36.49M |
| Gross Profit (TTM) | $-88.86M |
| EBITDA | $-119.94M |
| Operating Margin | -1167.00% |
| Return on Equity | -52.30% |
| Return on Assets | -27.10% |
| Revenue/Share (TTM) | $0.62 |
| Book Value | $3.32 |
| Price-to-Book | 1.31 |
| Price-to-Sales (TTM) | 6.29 |
| EV/Revenue | 3.329 |
| EV/EBITDA | 2.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -59.90% |
| Shares Outstanding | $60.42M |
| Float | $44.22M |
| % Insiders | 15.13% |
| % Institutions | 56.37% |
Historical Volatility
HV 10-Day
79.29%
HV 20-Day
66.65%
HV 30-Day
61.40%
HV 60-Day
71.27%
HV Rank
38.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($14.89 target)
12
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026